Curi RMB Capital LLC Raises Holdings in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Curi RMB Capital LLC increased its position in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 47.5% during the third quarter, Holdings Channel.com reports. The institutional investor owned 149,577 shares of the company’s stock after purchasing an additional 48,202 shares during the period. Curi RMB Capital LLC’s holdings in Allogene Therapeutics were worth $419,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC lifted its position in Allogene Therapeutics by 429.6% during the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock valued at $25,000 after purchasing an additional 8,734 shares during the last quarter. Federated Hermes Inc. purchased a new stake in shares of Allogene Therapeutics during the 2nd quarter valued at about $29,000. Phoenix Wealth Advisors bought a new position in shares of Allogene Therapeutics in the 2nd quarter valued at about $30,000. Private Advisor Group LLC purchased a new position in Allogene Therapeutics in the third quarter worth about $34,000. Finally, Algert Global LLC bought a new stake in Allogene Therapeutics during the second quarter worth approximately $35,000. 83.63% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on ALLO. Truist Financial reaffirmed a “buy” rating and issued a $14.00 price objective (down from $17.00) on shares of Allogene Therapeutics in a research note on Friday, August 9th. Citigroup lifted their price objective on shares of Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Canaccord Genuity Group cut their price objective on shares of Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a report on Thursday. Finally, Oppenheimer started coverage on shares of Allogene Therapeutics in a report on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $9.73.

Allogene Therapeutics Price Performance

Shares of ALLO opened at $2.27 on Friday. The firm has a market capitalization of $475.95 million, a price-to-earnings ratio of -1.46 and a beta of 0.84. The company has a 50-day moving average of $2.75 and a 200 day moving average of $2.66. Allogene Therapeutics, Inc. has a 1-year low of $2.01 and a 1-year high of $5.78.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).